1. Home
  2. IMOS vs CGEM Comparison

IMOS vs CGEM Comparison

Compare IMOS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMOS

ChipMOS TECHNOLOGIES INC.

HOLD

Current Price

$33.60

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.96

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMOS
CGEM
Founded
1997
2016
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
671.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IMOS
CGEM
Price
$33.60
$10.96
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$28.00
AVG Volume (30 Days)
14.4K
1.1M
Earning Date
02-24-2026
02-26-2026
Dividend Yield
1.99%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$748,307,671.00
N/A
Revenue This Year
$5.78
N/A
Revenue Next Year
$10.84
N/A
P/E Ratio
$157.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.78
$5.68
52 Week High
$32.51
$13.33

Technical Indicators

Market Signals
Indicator
IMOS
CGEM
Relative Strength Index (RSI) 71.69 56.55
Support Level $29.70 $9.41
Resistance Level $30.56 $10.70
Average True Range (ATR) 0.60 0.60
MACD 0.27 -0.05
Stochastic Oscillator 95.55 79.64

Price Performance

Historical Comparison
IMOS
CGEM

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: